Eam Investors, LLC Protagonist Therapeutics, Inc Transaction History

Eam Investors, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$18.02 - $29.36 $1.58 Million - $2.58 Million	87,953 New	87,953 $2.43 Million
Q3 2021 Nov 12, 2021	SELL	$12.95 - $49.69 $1.31 Million - $5.02 Million	-101,019 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$25.57 - $44.88 $2.58 Million - $4.53 Million	101,019 New	101,019 $4.53 Million
Q1 2021 May 11, 2021	SELL	$19.02 - $31.15 $838,154 - $1.37 Million	-44,067 Closed	0 $0
Q4 2020 Feb 11, 2021	SELL	$18.49 - $25.13 $559,858 - $760,911	-30,279 Reduced 40.73%	44,067 $888,000
Q3 2020 Nov 13, 2020	BUY	$15.19 - $22.4 $1.13 Million - $1.67 Million	74,346 New	74,346 $1.45 Million

248

56.7M

76.3K

114K

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $1.93B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

Get notified when there are updates to the investment portfolio of Eam Investors, LLC, based on Form 13F filings with the SEC.

Stay updated on Eam Investors, LLC with notifications on news.